Novel Vector for Making Transgenic Animals for Genetic Regulation
Search text
About 24 results
(0.10 seconds)
This targeted approach minimizes developmental compensation and offers detailed insights into immune regulation related to T cell function, cancer, autoimmunity, and infectious diseases. What differentiates this technology is its inducible nature, which offers unparalleled control over gene expression compared to traditional transgenic or constitutive knockout models. - Enables precise, cell-specific, and temporally controlled manipulation of Tim-3 expression.
Scientists from University of Pittsburgh have developed a novel approach to target cancer cells through the insertion of a “suicide gene” (HSV1-tk) into key gene fusion areas of the cancer genome. Two fusion gene breakpoints have been successfully targeted with an HSV gene. Targeting gene fusion points remains an elusive goal in cancer therapy.
Developed using novel mini promoters to enhance gene expression and a PWS-minigene adeno-associated virus (AAV) vector, it may be possible to treat this neurodevelopmental disorder. • Developmental disorders involving multiple genes. Given the large number of genes involved in PWS, traditional gene therapy is not a feasible option due to limits in delivering more than one gene using AAV vectors.